NewtekOne, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NewtekOne, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2021 to Q3 2024.
  • NewtekOne, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $918K, a 55.1% increase year-over-year.
  • NewtekOne, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $3.1M, a 20.2% increase year-over-year.
  • NewtekOne, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.8M, a 12% increase from 2022.
  • NewtekOne, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.5M, a 19% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $3.1M $918K +$326K +55.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $2.77M $656K -$29K -4.23% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $2.8M $700K $0 0% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $2.8M $823K +$223K +37.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 $2.58M $592K -$8K -1.33% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $2.59M $685K +$185K +37% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $2.4M $700K -$100K -12.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $2.5M $600K Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 $600K +$300K +100% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $500K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $800K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q3 2021 $300K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.